SI-BONE, Inc. is a medical device company specializing in minimally invasive surgical solutions for sacroiliac joint dysfunction, thoracolumbar fixation, and pelvic trauma. The company develops patented titanium implants and instruments, utilizing additive manufacturing and 3D-printing technologies to address low-density bone challenges. Its product portfolio includes the iFuse Implant System, iFuse 3D, iFuse TORQ, iFuse Bedrock Granite, iFuse TORQ TNT, and iFuse INTRA. SI-BONE markets its products primarily in the United States and the European Economic Area, serving orthopedic and spine surgeons. Founded in April 2008 as a spin-out from INBONE Technologies, the company has performed over 140,000 procedures using its implants since the introduction of the first-generation iFuse in 2009.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Medical Devices Homepage si-bone.com
Sector Healthcare IR page investor.si-bone.com
Tags
orthopedic implants, sacroiliac joint fusion, spinal fixation, pelvic trauma, 3d printing, titanium implants, minimally invasive surgery, bone grafting, iFuse, iFuse 3D, iFuse TORQ, iFuse Bedrock Granite, iFuse TORQ TNT, iFuse INTRA, iFuse INTRA X, iFuse Bone, iFuse Implant System, iFuse Technology
Press page —

Metrics

Valuation  
Market cap $ 1.043B
Market cap (USD) $ 1.043B
P/E -74.78
PEG —
P/BV 5.65
P/S 4.73
P/OCF 171.51
P/FCF -248.77
Dividend yield —
Turnover / mcap —
Returns  
ROE -11.0%
ROI -8.9%
ROIC -7.9%
Profit margin -9.4%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding Yes
Buying back stock No
Diluting (TTM) Yes
Debt/Equity 19.3%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 26
Quality score -29.4%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017
Revenue 200.925M 167.178M 138.886M 106.409M 90.152M 73.387M 67.301M 55.38M 47.983M
Net profit -18.904M -30.913M -43.336M -61.256M -56.572M -43.697M -38.403M -17.453M -23.039M
Free cash flow -9.089M -22.922M -26.512M -51.162M -45.922M -33.223M -34.072M -15.461M -18.008M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017
Share price 19.72 14.02 20.99 13.6 22.21 29.9 21.5 20.89 —
Price performance 12m 0.41 -0.33 0.54 -0.39 -0.26 0.39 0.03 — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — 7.42M 8.49M 11.7M 13.6M 14.2M 20.7M 22M 27.5M 29.9M
↳ YoY growth +14.4% +38.1% +16.1% +4.7% +45.1% +6.2% +25.1% +8.9%
↳ 5y CAGR +22.8% +20.9% +18.6% +17.1%
Borrowings, current (USD) — — 0.00 4.36M 0.00 0.00 — — — —
Borrowings, non-current (USD) — 38.7M 39M 34.9M 39.5M 35M 35.2M 36.1M 35.5M 35.6M
Lease liabilities (USD) — — — — 0.00 5.51M 4.26M 2.93M 2.03M 1.12M
Cash and deposits (USD) 27.9M 22.4M 25.1M 10.4M 53.6M 63.4M 20.7M 33.3M 34.9M 42.2M
Right-of-use assets (USD) — — — — 0.00 5.25M 4M 2.71M 1.98M 1.09M
Net debt (borrowings + leases - cash) (USD) — 16.3M 13.8M 28.8M -14.1M -22.9M 18.7M 5.72M 2.54M -5.55M
Cash flow detail
Operating cash flow (USD) — -17.5M -14.5M -31.6M -30.7M -39.5M -41.7M -18.7M -12.4M -675,000
Purchases of property, plant and equipment (USD) — -478,000 -942,000 -2.45M -2.56M -6.39M -9.51M -7.8M -10.5M -8.41M
Change in receivables (cash effect) (USD) — -1.31M -1.02M -3.24M -2.19M -569,000 -6.48M -2.12M -5.84M -3.03M
Change in inventories (cash effect) (USD) — -980,000 -759,000 -2.11M -274,000 -5.78M -5.71M -4.72M -8.05M -8.68M
Change in payables (cash effect) (USD) — 811,000 251,000 383,000 835,000 -532,000 2.53M -1.12M 1.86M -1.76M
Share buybacks (cash effect) (USD) — 0.00 -73,000 -38,000 — — — — — —
Interest paid (cash effect) (USD) — -4.51M -5.5M -4.95M -4.28M -3.23M -2.62M -3.26M -3.35M -2.53M
Share-based compensation (USD) — 1.44M 2.31M 7.46M 11.9M 16.9M 23.1M 24.1M 25.9M 25.5M
Operating cash flow before change in receivables (USD) — -16.2M -13.5M -28.4M -28.5M -39M -35.2M -16.6M -6.59M 2.35M
Free cash flow (OCF - PPE - intangibles) (USD) — -18M -15.5M -34.1M -33.2M -45.9M -51.2M -26.5M -22.9M -9.09M
Income detail
Research and development expense (USD) — 5.51M 5.38M 7.28M 9.46M 12.4M 13.6M 15M 16.6M 17.4M
↳ 5y CAGR +19.8% +22.8% +17.9% +13.0%
Total comprehensive income (USD) — -23.1M -17.4M -38.4M -43.6M -56.7M -61.4M -43.2M -31M -18.3M
Comprehensive income to owners (USD) — -23.1M -17.4M -38.4M -43.6M -56.7M -61.4M -43.2M -31M -18.3M
Provision for credit losses (USD) — — — 0.00 234,000 14,000 150,000 761,000 470,000 570,000
Credit cost ratio (credit losses / average receivables) (%) — — — 0.0% 1.8% 0.1% 0.9% 3.6% 1.9% 2.0%
Reported Nov 29, 2018 Mar 14, 2019 Mar 11, 2020 Mar 10, 2021 Mar 1, 2022 Aug 9, 2022 Mar 2, 2023 Feb 27, 2024 Feb 25, 2025 Feb 24, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

November 2, 2026 at 4:09 PM EST

PDF Version

Delivered ~20% U.S. procedure volume growth in the third quarter

Third Quarter 2026****Financial Highlights (all comparisons are to the prior year period)

  • Worldwide revenue of $55.7 million, representing growth of 14.5%

  • U.S. revenue of $52.8 million, representing growth of 13.9%

  • Gross margin of 79.3%

  • Net loss of $3.6 million, representing an improvement of 20.7%

  • Positive adjusted EBITDA of $3.0 million, representing an improvement of 32.4%

  • Positive cash from operations of $5.9 million, representing an improvement of 154.4%

  • $146.3 million in cash and equivalents

Recent Operational Highlights(any comparisons are to the prior year period)

  • 1,770 active U.S. physicians, representing growth of ~16%

  • In September, received 510(k) clearance for iFuse Granite Onyx, a FDA breakthrough device targeting failures in spine fusion procedures, with an estimated total addressable market of ~$1.5 billion annually

  • In October, new MS-DRGs took effect for complex spinal fusion procedures incorporating iFuse Bedrock Granite, increasing average hospital inpatient payments by up to ~$50,000 per qualifying procedure

SAN JOSE, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today reported financial results for the quarter ended September 30, 2026.

“Robust third-quarter growth in procedure volumes and active physicians underscores rising demand for our diversified and differentiated platform technologies,” said Laura Francis, Chief Executive Officer. “We enter the fourth quarter with a record number of active physicians, favorable DRG changes and exceptional early uptake in our alpha launch of iFuse Granite Onyx, our new platform technology that expands our estimated total addressable market to approximately $5 billion. These drivers position us for an excellent finish to 2026 and enter 2027 with the strongest foundation for growth acceleration in our company's history.”

Third Quarter 2026****Financial Results Worldwide revenue was $55.7 million in the third quarter 2026, a 14.5% increase from $48.7 million in the corresponding period in 2025. U.S. revenue for the third quarter 2026 was $52.8 million, a 13.9% increase from $46.4 million in the corresponding period in 2025. U.S. revenue growth benefited from approximately 19.5% growth in procedure volume partially offset by lower average selling price due to procedure mix and the growing interventional spine physician demand for the INTRA platform in the office-based and ASC sites of care. International revenue for the third quarter 2026 was $2.9 million, a 27.0% increase from $2.3 million in the corresponding period in 2025. International revenue growth reflects the increasing adoption of iFuse TORQ and iFuse TORQ TNT.

Gross profit was $44.2 million in the third quarter 2026, an increase of 13.7% from $38.8 million in the corresponding period in 2025. Gross margin was 79.3% for the third quarter 2026, compared to 79.8% in the corresponding period in 2025 driven by procedure and site of care mix.

Operating expenses increased 9.7% to $48.5 million in the third quarter 2026, as compared to $44.2 million in the corresponding period in 2025. The increase was primarily driven by higher sales commissions on increased revenue, marketing to support new product launches and continued investment in research and development.

Operating loss improved by 19.2% to $4.4 million in the third quarter 2026, as compared to an operating loss of $5.4 million in the corresponding period in 2025.

Net loss improved by 20.7% to $3.6 million, or $0.08 per diluted share, in the third quarter 2026, as compared to a net loss of $4.6 million, or $0.11 per diluted share, in the corresponding period in 2025.

Adjusted EBITDA was $3.0 million in the third quarter 2026, improving from an adjusted EBITDA of $2.3 million in the corresponding period in 2025.

Cash and equivalents as of September 30, 2026 were $146.3 million, compared to $145.9 million as of June 30, 2026. Net cash generated was $0.4 million in the third quarter 2026, compared to $0.2 million in net cash generated during the corresponding period in 2025.

Updated Fiscal2026Outlook SI-BONE reaffirms its previously issued 2026 worldwide revenue and gross margin guidance. Based on year to date operating expense trend the Company is reducing the operating expense growth expectation to 10.5%.

| | Fiscal Year 2026 Guidance |

| | Updated (November 2, 2026) | Prior (August 3, 2026) |

| Revenue | $231M - $233M ~15-16% growth | $231M - $233M ~15-16% growth |

| Gross Margin | ~79.0% | ~79.0% |

| Operating Expenses | ~10.5% growth at revenue midpoint | ~12.0% growth at revenue midpoint |

| Adjusted EBITDA | Positive | Positive |

Webcast Information SI-BONE will host a conference call to discuss the third quarter 2026 financial results after market close on Monday, November 2, 2026 at 4:30 P.M. Eastern Time. The conference call can be accessed live over webcast at https://edge.media-server.com/mmc/p/qa2u8o97. Live audio of the webcast will be available on the “Investors” section of the company’s website at: www.si-bone.com. The webcast will be archived and available for replay for at least 90 days after the event.

About SI-BONE, Inc. SI-BONE (NASDAQ: SIBN) is a global leader in developing procedural solutions to address clinical challenges associated with compromised bone. With expertise in biomechanical design and anatomy specific innovation, SI-BONE has built a technology platform with market-leading applications centered on the spinopelvic anatomy. SI-BONE continues to leverage the deep experience in addressing the challenges of low-density bone in the sacrum to develop unique technologies that are targeting new clinical adjacencies to help improve outcomes for patients with compromised bone. Since 2009, SI-BONE has supported physicians in over 160,000 procedures. A unique body of clinical evidence supports the use of SI-BONE's technologies, including four randomized controlled trials and nearly 200 peer-reviewed publications.

For additional information on the company or the products, including risks and benefits, please visit www.si-bone.com.

SI-BONE®, iFuse Bedrock Granite®, iFuse TORQ®, iFuse TORQ TNT®, iFuse Granite Onyx™, and iFuse INTRA® are trademarks of SI-BONE, Inc. All other marks referenced herein are property of their respective owners. ©2026 SI-BONE, Inc. All Rights Reserved.

Forward-Looking Statements The statements in this press release regarding expectations of future events or results, including SI-BONE’s expectations of continued revenue and procedure growth and financial outlook, are “forward-looking” statements. These forward-looking statements are based on SI-BONE’s current expectations and inherently involve significant risks and uncertainties. These risks include SI-BONE’s ability to introduce and commercialize new products and indications, SI-BONE’s ability to maintain favorable reimbursement for procedures using its products, the impact of any future economic weakness or deterioration in economic conditions as a result of tariffs and retaliation by U.S. trading partners on the ability and desire of patients to undergo elective procedures including those using SI-BONE’s products, SI-BONE’s ability to manage risks to its supply chain, future capital requirements driven by new surgical systems requiring instrument tray and implant inventory investment, and the pace of the re-normalization of the healthcare operating environment including the ability and desire of patients and physicians to undergo and perform procedures using SI-BONE’s products. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these and other risks and uncertainties, many of which are described in SI-BONE’s most recent filings on Form 10-K and Form 10-Q, and SI-BONE’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov), especially under the caption “Risk Factors.” SI-BONE does not undertake any obligation to update forward-looking statements and expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein, except as required by law.

Use of Non-GAAP Financial Measures To supplement our condensed consolidated financial statements, which are prepared and presented in accordance with generally accepted accounting principles in the United States ("GAAP"), SI-BONE uses two non-GAAP financial measures: Adjusted EBITDA and free cash flow. Non-GAAP measures should be considered supplemental to, and not a substitute for, financial information prepared in accordance with GAAP. Adjusted EBITDA excludes the effect of items that increase or decrease SI-BONE’s reported results of operations. Free cash flow is not intended to represent our residual cash flow available for discretionary expenditures. Management strongly encourages investors to review, when they become available, the company's consolidated financial statements and publicly filed reports in their entirety. The company's definition of adjusted EBITDA and free cash flow may differ from similarly titled measures used by others.

Adjusted EBITDA excludes from net loss the effects of interest income, interest expense, depreciation and amortization, and stock-based compensation. Free cash flow is defined as net cash provided by operating activities less purchases of property and equipment. SI-BONE believes the presentation of these financial measures is useful to management because it allows management to more consistently analyze period-to-period financial performance and provides meaningful supplemental information with respect to core operational activities used to evaluate management's performance. SI-BONE also believes the presentation of non-GAAP financial measures is useful to investors and other interested persons as it enables these persons to use this additional information to assess the company’s performance in using this additional metric that management uses to assess the company’s performance.

Investor Contact

Saqib Iqbal VP, FP&A, and Investor Relations [email protected]

| | | | |

| SI-BONE, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (In thousands, except share and per share amounts) (Unaudited) |

| | | | |

| | Three Months Ended September 30, | | Nine Months Ended September 30, |

| | | 2026 | | | | 2025 | | | | 2026 | | | | 2025 | |

| Revenue | $ | 55,704 | | | $ | 48,656 | | | $ | 164,302 | | | $ | 144,576 | |

| Cost of goods sold | | 11,537 | | | | 9,810 | | | | 33,643 | | | | 29,228 | |

| Gross profit | | 44,167 | | | | 38,846 | | | | 130,659 | | | | 115,348 | |

| Operating expenses: | | | | | | | |

| Sales and marketing | | 33,850 | | | | 29,956 | | | | 100,682 | | | | 91,418 | |

| Research and development | | 4,562 | | | | 4,242 | | | | 13,975 | | | | 13,085 | |

| General and administrative | | 10,106 | | | | 10,031 | | | | 30,252 | | | | 30,712 | |

| Total operating expenses | | 48,518 | | | | 44,229 | | | | 144,909 | | | | 135,215 | |

| Loss from operations | | (4,351 | ) | | | (5,383 | ) | | | (14,250 | ) | | | (19,867 | ) |

| Interest and other income (expense), net: | | | | | | | |

| Interest income | | 1,348 | | | | 1,515 | | | | 4,030 | | | | 4,627 | |

| Interest expense | | (608 | ) | | | (670 | ) | | | (1,798 | ) | | | (1,998 | ) |

| Other income (expense) | | (9 | ) | | | (28 | ) | | | (24 | ) | | | (22 | ) |

| Net loss | $ | (3,620 | ) | | $ | (4,566 | ) | | $ | (12,042 | ) | | $ | (17,260 | ) |

| | | | | | | | |

| Net loss per share, basic and diluted | $ | (0.08 | ) | | $ | (0.11 | ) | | $ | (0.27 | ) | | $ | (0.40 | ) |

| | | | | | | | |

| Weighted-average number of common shares used to compute basic and diluted net loss per share | | 44,899,517 | | | | 43,188,524 | | | | 44,451,298 | | | | 42,775,206 | |

| | | | |

| SI-BONE, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands) (unaudited) |

| | | | |

| | September 30, 2026 | | December 31, 2025 |

| ASSETS | | | |

| Current assets: | | | |

| Cash and cash equivalents | $ | 35,311 | | | $ | 42,240 | |

| Short-term investments | | 110,949 | | | | 105,583 | |

| Accounts receivable | | 31,469 | | | | 29,915 | |

| Inventory | | 42,354 | | | | 33,897 | |

| Prepaid expenses and other current assets | | 4,567 | | | | 4,480 | |

| Total current assets | | 224,650 | | | | 216,115 | |

| Property and equipment, net | | 25,304 | | | | 21,298 | |

| Operating lease right-of-use assets | | 6,613 | | | | 1,087 | |

| Other non-current assets | | 204 | | | | 55 | |

| TOTAL ASSETS | $ | 256,771 | | | $ | 238,555 | |

| | | | |

| LIABILITIES AND STOCKHOLDERS’ EQUITY | | | |

| Current liabilities: | | | |

| Accounts payable | $ | 10,503 | | | $ | 4,631 | |

| Accrued liabilities and other | | 18,785 | | | | 19,704 | |

| Operating lease liabilities, current portion | | 331 | | | | 944 | |

| Total current liabilities | | 29,619 | | | | 25,279 | |

| Long-term borrowings | | 35,657 | | | | 35,569 | |

| Operating lease liabilities, net of current portion | | 6,813 | | | | 175 | |

| TOTAL LIABILITIES | | 72,089 | | | | 61,023 | |

| | | | |

| STOCKHOLDERS’ EQUITY | | | |

| Common stock | | 4 | | | | 4 | |

| Additional paid-in capital | | 646,696 | | | | 626,970 | |

| Accumulated other comprehensive income | | 282 | | | | 816 | |

| Accumulated deficit | | (462,300 | ) | | | (450,258 | ) |

| TOTAL STOCKHOLDERS’ EQUITY | | 184,682 | | | | 177,532 | |

| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $ | 256,771 | | | $ | 238,555 | |

| | | | | |

| SI-BONE, INC. RECONCILIATION OF NET LOSS TO NON-GAAP ADJUSTED EBITDA (In thousands) (unaudited) |

| | | | | |

| | | Three Months Ended September 30, | | Nine Months Ended September 30, |

| | | | 2026 | | | | 2025 | | | | 2026 | | | | 2025 | |

| Net loss | | $ | (3,620 | ) | | $ | (4,566 | ) | | $ | (12,042 | ) | | $ | (17,260 | ) |

| Interest income | | | (1,348 | ) | | | (1,515 | ) | | | (4,030 | ) | | | (4,627 | ) |

| Interest expense | | | 608 | | | | 670 | | | | 1,798 | | | | 1,998 | |

| Depreciation and amortization | | | 1,693 | | | | 1,486 | | | | 4,989 | | | | 4,132 | |

| Stock-based compensation | | | 5,713 | | | | 6,226 | | | | 17,717 | | | | 19,547 | |

| Adjusted EBITDA | | $ | 3,046 | | | $ | 2,301 | | | $ | 8,432 | | | $ | 3,790 | |

| | | |

| SI-BONE, INC. RECONCILIATION OF FREE CASH FLOW (In thousands) (unaudited) |

| | | |

| | | Nine Months Ended September 30, |

| | | | 2026 | | | | 2025 | |

| Net cash provided by (used in) operating activities | | $ | 4,355 | | | $ | (2,403 | ) |

| Less: | | | | |

| Purchases of property and equipment | | | (8,989 | ) | | | (7,126 | ) |

| Free cash flow | | $ | (4,634 | ) | | $ | (9,529 | ) |

Primary Logo

Source: SI-BONE, Inc.

Get the iFuse Patient Newsletter

Looking for Answers?

We can help. Tell us what you're looking for below.

October 29, 2026 at 5:43 PM EDT

PDF Version

SAN JOSE, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced that the company will be participating in the upcoming UBS Global Healthcare Conference in Palm Beach Gardens, FL. Management will be hosting a fireside chat on Tuesday, November 10, 2026, at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time.

Investors interested in listening to the conference call may do so by registering at this link SI-BONE, Inc. - 1781346. Live audio of the webcast will be available on the “Investors” section of the company’s website at: www.si-bone.com. The webcast will be archived and available for replay for at least 90 days after the event.

About SI-BONE, Inc.

SI-BONE (NASDAQ: SIBN) is a global leader in developing procedural solutions to address clinical challenges associated with compromised bone. With expertise in biomechanical design and anatomy specific innovation, SI-BONE has built a technology platform with market-leading applications centered on the spinopelvic anatomy. SI-BONE continues to leverage the deep experience in addressing the challenges of low-density bone in the sacrum to develop unique technologies that are targeting new clinical adjacencies to help improve outcomes for patients with compromised bone. Since 2009, SI-BONE has supported physicians in performing over 150,000 procedures. A unique body of clinical evidence supports the use of SI-BONE's technologies, including four randomized controlled trials and over 190 peer reviewed publications.

For additional information on the company or the products, including risks and benefits, please visit www.si-bone.com.

SI-BONE® is a registered trademark of SI-BONE, Inc. ©2026 SI-BONE, Inc. All Rights Reserved.

Investor Contact: Saqib Iqbal [email protected]

Primary Logo

Get the iFuse Patient Newsletter

Looking for Answers?

We can help. Tell us what you're looking for below.

October 19, 2026 at 4:09 PM EDT

PDF Version

SAN JOSE, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (NASDAQ: SIBN), a global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced it will report financial results for the third quarter of 2026 after market close on Monday, November 2, 2026. Management will host a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Investors interested in listening to the conference call may do so by registering at this link: https://edge.media-server.com/mmc/p/qa2u8o97/. Live audio of the webcast will be available on the “Investors” section of the company’s website at: www.si-bone.com. The webcast will be archived and available for replay for at least 90 days after the event.

About SI-BONE, Inc.

SI-BONE (Nasdaq: SIBN) is a global leader in developing procedural solutions to address clinical challenges associated with compromised bone. With expertise in biomechanical design and anatomy specific innovation, SI-BONE has built a technology platform with market-leading applications centered on the spinopelvic anatomy. SI-BONE continues to leverage the deep experience in addressing the challenges of low-density bone in the sacrum to develop unique technologies that are targeting new clinical adjacencies to help improve outcomes for patients with compromised bone. Since 2009, SI-BONE has supported physicians in performing over 150,000 procedures. A unique body of clinical evidence supports the use of SI-BONE's technologies, including four randomized controlled trials and over 190 peer reviewed publications.

For additional information on the company or the products, including risks and benefits, please visit www.si-bone.com.

SI-BONE® is a registered trademark of SI-BONE, Inc. ©2026 SI-BONE, Inc. All Rights Reserved

Investor Contact: Saqib Iqbal, [email protected]

Primary Logo

Get the iFuse Patient Newsletter

Looking for Answers?

We can help. Tell us what you're looking for below.

Prompts

SI-BONE, Inc. (ticker SIBN), listed in United States.

ETFs Holding SI-BONE, Inc.

ETF Weight in ETF Shares Market value As of
WCEO 0.51% 2,865 $ 50.882K Jul 31, 2026
OASC 0.24% 12,097 $ 230.085K Aug 31, 2026
ESSC 0.16% 3,167 $ 56.246K Jul 31, 2026
PSC 0.05% 72,345 $ 1.181M Jun 30, 2026
RESM 0.03% 72 $ 1,175.04 Jun 30, 2026
AVSC 0.03% 42,441 $ 993.544K Nov 16, 2026
DFAS 0.02% 277,132 $ 6.69M Nov 12, 2026
MSSM 0.00% 1,773 $ 33.722K Aug 31, 2026
DFAC 0.00% 102,962 $ 2.486M Nov 12, 2026
DCOR 0.00% 44,571 $ 1.076M Nov 12, 2026
DFSU 0.00% 2,064 $ 49.825K Nov 12, 2026
DFUS 0.00% 14,756 $ 356.21K Nov 12, 2026
DFAU 0.00% 8,441 $ 203.766K Nov 12, 2026
DXUV 0.00% 922 $ 22.257K Nov 12, 2026